Moderna shares rose after the FDA accepted a revised application for its seasonal flu vaccine, mRNA-1010. The company proposed a dual-pathway strategy for adults aged 50 and older, setting a target review date of August 5, 2026. This follows a prior refusal by the FDA last week. Moderna submitted the new approach to streamline approval based on age-specific indications.